Free Access
Tableau II.
Système G4e des variants d’IgG4.
| Numérotation G4e | Dénominations communes internationales | Année de première mise sur le marché | Nature de l’ingénierie de la chaîne lourde (Numérotation Eu) |
|---|---|---|---|
| G4e0 | natalizumab, ibalizumab | 2004 | Aucune ingénierie |
| G4e1 | gemtuzumab ozogamicin, pembrolizumab, nivolumab, cémiplimab | 2000 | Substitution S228P |
| G4e2 (ou G2e1) | éculizumab | 2007 | Hybride IgG2 (avant T260) / IgG4 (après) |
| G4e3 | dulaglutide | 2014 | Substitutions S228P, F234A, L235A et délétion K447 |
| G4e4 | ixékizumab, dupilumab | 2016 | Substitution S228P et délétion K447 |
| G4e5 | émicizumab | 2017 | Substitutions S228P, K196Q, F296Y, E356K, R409K, H435R, L445P et délétions G446, K447 |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.